Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $52 from $49 and keeps an Outperform rating on the shares following quarterly results. The firm notes the company expects topline data including PFS to be presented approximately the last week of March for the Phase 2/3 OpimUM-02 trial, evaluating darovasertib plus crizotinib in metastatic uveal melanoma, following 130 required PFS events confirmed by BICR in the study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Buy Rating on Darovasertib/Crizotinib Ahead of Pivotal OpतimUM-02 Readout and Supported by Strong Cash Runway
- Ideaya Biosciences reports Q4 EPS (94c), consensus (95c)
- Ideaya Biosciences price target raised to $45 from $41 at RBC Capital
- Multiple Shots on Goal in High-Unmet-Need Oncology: IDEAYA’s Diversified Pipeline and Strong Funding Underpin Buy Rating
- IDEAYA updates precision oncology strategy at JPM 2026